Table 3.

Randomized acute ischemic syndrome trials for intravenous glycoprotein IIb/IIIa blockade

Trial (number of patients)	Agent tested	Entry criteria	Primary endpoints
PURSUIT (10,948)	Eptifibatide	CP at rest or minimal exertion within	Death, and non-fatal MI, at 30 days
		24 hours and either ischemic ECG
		changes* or CK-MB elevations
PRISM-PLUS (1915)	Tirofiban	CP at rest or minimal exertion within	Death, MI, or refractory ischemia, at 7 days
		12 hours and either ischemic ECG
		changes* or CK-MB elevations
PRISM (3232)	Tirofiban	CP at rest or minimal exertion within	Death, MI or refractory ischemia, at 48 hours
		24 hours and ischemic ECG changes*
		or CK-MB elevations or history of CAD or
		positive stress test
PARAGON A (2282)	Lamifiban	CP at rest within 12 hours and ischemic	Death, and non-fatal MI, at 30 days
		ECG changes*
PARAGON B (5225)	Lamifiban	Patients within 12 hours of symptoms of	The composite incidence of death, MI, or SRI, at
		acute myocardial ischemia and ECG changes*	30 days
GUSTO IV-ACS (7800)	Abciximab	ACS within last 24 hours; > 5 min anginal	All-cause mortality, composite endpoint of death,
		symptoms at rest, and either + troponin I/T,	or MI, at 30 days
		or ST depression ≥ 0.5 mm

ACS, Acute coronary syndromes; CAD, coronary artery disease; CK-MB, creatine kinase MB isoenzyme; CP, Chest pain; ECG, electrocardiogram; MI, myocardial infarction; SRI, severe refractory ischemia. ^* ST depression, T inversion or transient ST elevation.